Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on Fractyl Health, Inc. (GUTS – Research Report) and keeping the price target at $10.00.
Michael Ulz has given his Buy rating due to a combination of factors that highlight the potential of Fractyl Health, Inc.’s ongoing studies. The early data from the REVEAL-1 cohort indicates promising signs of weight maintenance, with most patients experiencing less weight regain than anticipated after GLP-1 withdrawal. This suggests that Fractyl Health’s approach may offer a significant benefit in weight management.
Additionally, the safety profile appears favorable, as no severe adverse events were reported among the participants. The anticipation of further data from the REMAIN-1 study, which is over halfway enrolled, adds to the optimism. The upcoming mid-point analysis in the third quarter of 2025 is expected to provide deeper insights into the efficacy and durability of their treatment, reinforcing the potential for positive outcomes in the larger patient population.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GUTS in relation to earlier this year.